Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06924320 · ClinicalTrials.gov registry record · Phase 1
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
A Phase 1 study of Obesity and Obesity-related Medical Conditions, sponsored by Metsera, a wholly owned subsidiary of Pfizer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 132
- Enrollment target
- 1
- Study location
NCT06924320: Recruiting Phase 1 study of Obesity and Obesity-related Medical Conditions, sponsored by Metsera, a wholly owned subsidiary of Pfizer.
NCT06924320 is a Phase 1 study of Obesity and Obesity-related Medical Conditions that is actively recruiting participants, run by Metsera, a wholly owned subsidiary of Pfizer. The registered enrollment target is 132 participants, below the 527-participant average among 13 other Obesity and Obesity-related Medical Conditions trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06924320, a Phase 1 study of Obesity and Obesity-related Medical Conditions, is actively recruiting participants, sponsored by Metsera, a wholly owned subsidiary of Pfizer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 132 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to test how well the combination of MET233 with MET097 works to treat individuals with obesity or overweight with or without diabetes.
Primary Outcome
For Part A, B, C, D, E and G
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MET233 and MET097
- DRUG MET233
Study Locations (1)
California
- Research Site MET233/097 24-101-001 - Cypress
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2025-03-03 |
| Est. Completion | 2027-03-15 |
| Phase | Phase 1 |
What NCT06924320 shows while recruiting
NCT06924320 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, below the 527-participant average among 13 other Obesity and Obesity-related Medical Conditions trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Obesity and Obesity-related Medical Conditions appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06924320 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06924320 about?
NCT06924320 is a clinical study titled "A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes". This study is designed to test how well the combination of MET233 with MET097 works to treat individuals with obesity or overweight with or without diabetes.
What is the current status of trial NCT06924320?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 132 participants. The study started on 2025-03-03. Estimated completion is 2027-03-15.
What conditions does trial NCT06924320 study?
This clinical trial studies the following conditions: Obesity and Obesity-related Medical Conditions.
What interventions are being tested in trial NCT06924320?
The interventions under investigation include: Placebo (DRUG), MET233 and MET097 (DRUG), MET233 (DRUG).
Who is sponsoring clinical trial NCT06924320?
This trial is sponsored by Metsera, a wholly owned subsidiary of Pfizer, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06924320 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity and Obesity-related Medical Conditions
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06924320's enrollment target sits among peer trials
132 2nd of 13 the highest of 13 other Obesity and Obesity-related Medical Conditions trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity and Obesity-related Medical Conditions trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Research Evaluating Smoking Cessation With E-Cigarettes and Nicotine Therapy
RECRUITING · NA
-
Five PLus Year EffIcacy of Endoscopic Sleeve Gastroplasty (ESG) for Sustained WeigHT Loss
RECRUITING
-
New Mechanisms of Obesity
RECRUITING · NA
-
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
RECRUITING
-
MAINTAIN (Mucosal AblatIoN Therapy After INcretins)
RECRUITING · NA
-
REvision of VSG with Ablation of the Mucosa Procedure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI